HVEM Variants for Selective BTLA Binding in Autoimmune Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and inflammatory disorders, such as rheumatoid arthritis, often fail to respond adequately, as they primarily target TNF pathways without effectively addressing T cell and innate immune responses, leading to incomplete suppression of inflammation and potential tumor growth due to the complexity of HVEM-BTLA signaling pathways.
Innovation Solution
Development of HVEM polypeptide variants that specifically bind to BTLA without interacting with CD160 or other ligands, such as LIGHT and LTα, to modulate immune responses and inhibit inflammatory and tumor cell growth by using UL144 as a structural and functional mimic, allowing for targeted therapeutic interventions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If TNF inhibitors are used to block TNF binding to its receptors, then proinflammatory pathway is halted and innate inflammatory cells are quenched, but T cell responses are not effectively addressed and homeostasis is not reestablished
Solution Approach 1:
The invention segments the inflammatory pathway targeting approach by developing separate therapeutic agents for different pathways: TNF inhibitors for the proinflammatory pathway and HVEM-BTLA pathway modulators for T cell regulation. This segmentation allows each agent to specifically address its target pathway without interference, resolving the contradiction by enabling comprehensive coverage of both innate and adaptive immune responses through combined or sequential therapy.
Solution Approach 2:
The invention introduces HVEM-BTLA pathway modulation as an intermediary mechanism to bridge the gap left by TNF inhibitors. While TNF inhibitors directly block proinflammatory signaling, the HVEM-BTLA pathway acts as an intermediary regulatory system that modulates T cell responses and restores homeostasis, thereby extending the therapeutic effect beyond what TNF inhibitors alone can achieve.
2Adaptability or versatility
If HVEM binds to multiple ligands including LIGHT, BTLA, and CD160, then broad immune regulation is achieved, but tissue and cell-specific effects cannot be discriminated due to complexity of ligand interactions
Solution Approach 1:
The invention applies local quality by developing HVEM variants with engineered ligand binding specificities. Instead of using wild-type HVEM that binds multiple ligands (LIGHT, BTLA, CD160), the patent creates variants that selectively bind to specific ligands based on the therapeutic indication. For example, certain variants are designed to preferentially bind BTLA for autoimmune disease treatment, while others may target LIGHT for cancer therapy. This localized specificity reduces the complexity of ligand interactions while maintaining broad immune regulation capability across different disease contexts.
Solution Approach 2:
The invention utilizes parameter changes by modifying the binding affinity parameters of HVEM for different ligands. Through amino acid substitutions and structural engineering, the patent alters the dissociation constants and binding kinetics of HVEM variants for specific ligands. This allows optimization of the HVEM-ligand interaction parameters to achieve desired tissue and cell-specific effects, thereby discriminating between different therapeutic targets while maintaining broad immune regulation potential.
3Reliability
If CD160 activates positive signals in lymphocytes in response to HVEM ligation, then lymphocyte response is enhanced, but inflammatory responses may be exacerbated
Solution Approach 1:
The invention applies inversion by developing HVEM variants that invert the normal signaling outcome. Instead of using wild-type HVEM that activates CD160 and produces positive lymphocyte signals (which may exacerbate inflammation), the patent creates variants that preferentially engage BTLA to deliver inhibitory signals. This inverts the net effect from proinflammatory to antiinflammatory while maintaining lymphocyte response regulation, thereby resolving the contradiction between reliable lymphocyte activation and inflammatory control.
Data Source
Figure 1A~1C
Figure 2A~2C
Figure 3A~4B
AI summary
Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.